Indications for VISIPAQUE 270:
Intra-arterial: Digital subtraction angiography. IV: CECT imaging of the head and body, excretory urography, and peripheral venography.
Usual single doses: Intra-arterial digital subtraction angiography: Renal arteries: 10–25mL; Aortography: 20–50mL; Major branches of aorta: 5–30mL; max 250mL. IV: CECT of head or body: 75–150mL bolus or 100–150mL infusion; max 150mL. Excretory urography (normal renal function): 1mL/kg; max 100mL. Venography (per lower extremity): 50–150mL; max 250mL.
<1yr: not recommended. ≥1yr: IV CECT or excretory urography: 1–2mL/kg; max 2mL/kg.
Intrathecal use. Children: Prolonged fasting and laxative administration before Visipaque injection.
Should be administered by professional trained in use of radiopaque agents in appropriate facilities with emergency treatment readily available. Homocystinuria: avoid. Severe renal impairment. Combined renal and hepatic disease. Combined renal and cardiac disease. CHF. Diabetes. Severe thyrotoxicosis. Myelomatosis. Anuria. Pheochromocytoma. Homozygous sickle cell disease. Immune deficiency disorder. Maintain adequate hydration. Avoid extravasation. Children: asthma, cyanotic and acyanotic heart disease, CHF, serum creatinine >1.5mg/dL, immature renal function, dehydration: increased risk of adverse effects. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.
Radiographic contrast medium.
Recently received cholecystographic agents in patients with hepatic or biliary disorder; increased risk of renal toxicity. Do not mix with other drugs. Radioactive iodine uptake studies may not accurately reflect thyroid function for up to 16 days.
Rash, erythema, pruritus, scotoma; thromboembolic events, hypersensitivity reactions, others.